You have reached the legacy site. Please visit our new site at

HIV and Coverage of the
46th Annual Meeting of the European
Association for the Study of the Liver

 March 30 - April 3, 2011, Berlin, Germany
  The material posted on HIV and about EASL 2011 is not approved by nor is it a part of EASL 2011.
Library of Slides and Posters
Hepatitis B Articles
Hepatitis C Articles

    Google Custom Search
Hepatitis C Articles
EASL Releases New Hepatitis C Clinical Practice Guidelines
Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
Tegobuvir Works Well in Triple and Quad Regimens for HCV
Boosted Danoprevir Improves Response in Prior Null Responders
Once-Daily BI201335 Ups Response to Interferon for Hepatitis C
BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
Statin Boosts Response to Pegylated Interferon/Ribavirin
Boceprevir Helps Hepatitis C Patients with Cirrhosis
TMC435 Beats Standard Therapy Regardless of HCV Genotype
Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
Pegylated Interferon Lambda Boosts Response with Few Side Effects
First Sustained Response Data for Polymerase Inhibitor Mericitabine
4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab
Hepatitis B Articles
Kidney Toxicity Uncommon among People Taking Tenofovir for Hepatitis B
HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
Library of Slides and Posters
Baseline Genotype And HBsAg Were Found To Have Signifi cant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment
J Heathcote and others. EASL 2011.
Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist
D Tumas and others. EASL 2011.
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
R Lanford and others. EASL 2011.
Anti-Viral Effi cacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection
S Menne and others. EASL 2011.
Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon a-2a and Ribavirin in the PILLAR Study
J Aerssens and others. EASL 2011.
Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin
O Lenz and others. EASL 2011.
Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment
V Sekar and others. EASL 2011.
The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis
S Zeuzem and others. EASL 2011.
First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects
S Pol and others. EASL 2011.
A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
E Lawitz and others. EASL 2011.
Interim Results of a Randomized Treatment Study of Emtricitabine/Tenofovir DF (FTC/TDF) and HBIG Withdrawal in Post-Orthotopic Liver Transplant (OLT) Recipients for CHB
L Tepperman and others. EASL 2011.
Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
A Corsa and others. EASL 2011.
Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB)
S Fung and others. EASL 2011.
Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies
P Marcellin and others. EASL 2011.
A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects
U Lopatin and others. EASL 2011.
HBsAg Kinetics in Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumurate (TDF) for up to 4 years
P Marcellin and others. EASL 2011.


EASL 2011 News